Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 62

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 62
---
2) vaccine (intramuscular injection)      Biologic                For the prevention of infectious disease caused by SARS-CoV-2 (monovalent vaccine based on Omicron JN.1 variant）                  Japan         Approved (Sep 2024)  
  TAK-003                                Tetravalent dengue vaccine (injection)                                      Biologic and other      For the prevention of dengue fever of any severity, due to any serotype, in individuals aged 4 and older (booster extension)      -             P-III                

____________

Note:

(1) Partnership with Novavax, Inc.

Select Options: Other Selected Assets That Takeda Holds Contractual Rights to Potentially Clinically Develop and/or Commercialize in the Future

Other selected assets that Takeda holds contractual rights to potentially clinically develop and/or commercialize in the future as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, are as follows:

  Development code      Type of Drug                                        Modality                Indications / additional formulations       Country/      Stage  
  HQP1351 1             BCR-ABL tyrosine kinase inhibitor (TKI) (oral)      Small molecule          Chronic phase-chronic myeloid leukemia      U. S.         P-III  
  ACI-24.060 2          Abeta active immunotherapy                          Biologic and other      Alzheimer’s disease                         -             P-II   

____________

Notes:

(1) Olverembatinib/HQP1351 is included for reference only. Ascentage Pharma retains ownership of this asset and is solely responsible for its clinical development prior to Takeda’s potential exercise of its option to exclusively license certain rights, which is subject to customary conditions including regulatory approval.

(2) ACI-24.060 is included for reference only. AC Immune retains ownership of this asset and is solely responsible for its clinical development prior to Takeda’s potential exercise of its option to exclusively license certain rights, which is subject to customary conditions including regulatory approval.

Table of Contents

Projects removed from pipeline

Our projects removed from pipeline since April 1, 2024 are as follows:

  Development code       Indications (Region/Country, Stage)                                                                                                      Reason                                                                                                                                                                                                
  <generic name>                                                                                                                                                                                                                                                                                                                                                        
  TAK-141/JR-141         Hunter syndrome (CNS and somatic symptoms) (EU, P-